We have always encouraged dialogue with our investors and understandably some have been in touch, not only to express their disappointment, but also to seek answers as to why the fund’s recent performance has suffered. In the following video, Neil explains events and what they mean for the fund’s strategy
Earlier today, AstraZeneca announced initial trial data from its phase III Mystic study for its potential combination therapy for lung cancer. Neil gives his view on the announcement.
So we’ve had another election and received another surprise. In all the heat and light that accompanies an unexpected political outcome, a lot of extreme conclusions have been discussed by market and media commentators. From where I’m sitting, however, economically not a lot has changed. In fact, in some respects, the outlook for the UK economy has improved…
Today marks the publication of the Woodford Patient Capital Trust annual report. You can download the full report here, but below is Neil’s review of the trust’s progress in 2016. Download as a PDF We began 2016 with the money raised at the launch of WPCT fully deployed – and so the period under review
The offer period for the CF Woodford Income Focus Fund closed on 12 April 2017 and we can now confirm that £553m has been raised. Daily pricing of the fund has now commenced (you can find the latest price here), and Neil has been busy building the portfolio over the last few days, a process
Whilst travelling around the country recently for the launch of the Income Focus Fund, Neil has regularly been asked why this an appropriate time to be launching a new equity-based fund.
The saying goes, cash is king. Yet £10,000 invested in cash 10 years ago is worth £8,600 in real terms – a loss of 14%! Cash has its uses but perhaps sitting in a cash ISA for years on end isn’t one of them. Is it time to reassess your risk versus return?